Inhibitory Activity of Astragaloside Ⅳ on Proliferation of Aorta Vascular Smooth Muscle Cells in Rats

YANG Yong,XIAO Shang-zhi,GE Ya-kun,ZHENG Xiao-xiang
DOI: https://doi.org/10.16289/j.cnki.1002-0837.2011.02.008
2011-01-01
Abstract:Objective To investigate the inhibitory effects of Astragaloside Ⅳ on the proliferation of abnormal vascular smooth muscle cells (VSMCs). Methods VSMCs obtained from thoracic aorta of SD rats were cultured in vitro. The changes of cell proliferation, cell apoptosis, NO and Ca<'2+> concentration before and after Astragaloside Ⅳ administration in VSMCs were measured. Cell proliferation was measured with tetrazolium salt WST-1 assay. Cell apoptosis was assayed with flow cytometry through the detection of annexin Ⅴ. NO and in-tracellular Ca<'2+> concentration were measured by using confocal laser scanning microscopy with diaminofluorescein diacetate and Flue-3/AM, respectively. Cell aldose reductase (AR) activity was measured with absorbent spectrum of NADPH at 340 nm. Results WST assay showed that cell proliferation induced by serum was significantly inhibited by Astragaloside Ⅳ(P<0.01 ). Analysis on flow cytometry revealed that Astragaloside Ⅳ could enhance the apoptotic rate of VSMCs (P<0.01). The AR activity of VSMCs was markedly inhibited by both Astragaloside Ⅳ and an AR inhibitor, epalrestat (P<0.01). NO production was significantly enhanced after the administration of Astragaloside Ⅳ or interleukin-1β. Furthermore, Astragaloside Ⅳ increased cytosolic Ca<'2+> significantly. Conclusion Astragaloside Ⅳ may inhibit the proliferation of VSMCs associated with serum by inhibiting AR activity, augmenting apoptosis, and increasing the levels of cytosolic Ca<'2+> and NO production in VSMCs.
What problem does this paper attempt to address?